Theralase(TM) Retains Leading Investor Relations Firm

    TORONTO, Sept. 12 /CNW/ - Theralase(TM) Technologies Inc. (TSX-V: TLT &
OTC BB: TLTFF) ("Theralase"), a designer, manufacturer and distributor of
therapeutic medical laser systems, announced today that it has retained The
Equicom Group Inc. ("Equicom") to provide the Company with strategic investor
relations and financial communications services.
    Equicom provides strategic communications services to approximately
100 public companies across a diverse range of industries. Under the terms of
the agreement, Theralase will pay Equicom a monthly retainer fee of $5,000 for
professional services. The initial contract term is 6 months. Neither Equicom
nor any of its principals has an ownership interest, directly or indirectly,
in Theralase or its securities, and the Company has not granted Equicom or its
principals any right to acquire such an interest. Equicom, a wholly-owned
subsidiary of TSX Group Inc., is headquartered in Toronto, with offices in
Montreal and Calgary. For further information, please visit

    About Theralase Technologies Inc.

    Theralase Technologies Inc. designs, manufactures and distributes
patented, super-pulsed laser technology used in a wide range of
bio-stimulation and bio-destruction clinical applications. The Theralase
technology platform targets several diverse healthcare sectors -- firstly, for
non-invasive pain management and clinical therapy, in hundreds of neural
muscular skeletal conditions, including arthritis -- secondly, to
bio-stimulate and accelerate wound care and healing, including; bone fracture
regeneration and osteoarthritic conditions -- and thirdly, combining
photodynamic compounds with super-pulsed, biofeedback laser technology to
attack specifically targeted cancers, bacterium, viruses and fat cells.
    For a complete profile of Theralase Technologies Inc. and its products
visit the corporate website,, and the regulatory website at

    This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation
to update these forward-looking statements.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of the contents of this

For further information:

For further information: Roger Dumoulin-White, Theralase Technologies
Inc., President & CEO, (416) 447-8455,; Vanessa
Beresford, The Equicom Group Inc., (416) 815 0700, ext 227,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890